You are viewing: South Korea Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The South Korea Nuclear Medicine Market was valued at $159.3 Million in 2025 and projected to reach to $352.5 Million by 2030, representing a compound annual growth rate of 17.2%. South Korea's nuclear medicine market is poised for exceptional growth through 2030, driven by demographic shifts, rising chronic disease prevalence, and substantial healthcare investments.

South Korea Nuclear Medicine Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Nuclear Medicine Market Trends and Insights

  • This represents a compound annual growth rate (CAGR) of 17.2%, significantly outpacing global trends.
  • South Korea's advanced healthcare infrastructure, aging population, and increasing prevalence of chronic diseases are driving demand for diagnostic and therapeutic nuclear medicine applications. The South Korean nuclear medicine sector benefits from strong government support for healthcare innovation and substantial investments in medical imaging technology.
  • South Korea's emphasis on precision medicine and early disease detection has accelerated adoption of PET-CT and SPECT imaging modalities.
  • By 2030, South Korea is expected to consolidate its position as a leading nuclear medicine market in the Asia Pacific region, supported by rising healthcare expenditure and expanding clinical applications in oncology, cardiology, and neurology..

Key Market Statistics

  • CAGR (2025-2030) 17.2% CAGR
  • Market Size, 2025 ~USD 159.3 Million
  • Forecast, 2030 ~USD 352.5 Million
  • Country South Korea

South Korea Nuclear Medicine Market Overview

Fastest Growing Market in Asia-Pacific :

South Korea's nuclear medicine market is expanding at 17.2% CAGR, significantly outpacing the global growth rate of 15.1%, positioning it as a regional leader in adoption and innovation.

Aging Population Driving Demand :

With a rapidly aging demographic, South Korea faces increasing prevalence of cancer, cardiovascular diseases, and neurological disorders, creating sustained demand for diagnostic and therapeutic nuclear medicine procedures.

Advanced Healthcare Infrastructure :

South Korea's state-of-the-art medical facilities, high healthcare spending, and strong regulatory framework support rapid adoption of cutting-edge nuclear medicine technologies and radiopharmaceuticals.

Market Valuation Growth :

The market is projected to more than double from USD 159.3 million in 2025 to USD 352.5 million by 2030, reflecting strong investment and commercialization opportunities in the sector.

South Korea Nuclear Medicine Market Dynamics

  • The country's advanced medical infrastructure and high adoption rates of innovative diagnostic technologies create a favorable environment for market expansion.
  • Government initiatives supporting precision medicine and early disease detection further accelerate market penetration. The forecast period will witness increased demand for PET-CT imaging, radiopharmaceutical therapies, and hybrid imaging modalities.
  • Strategic partnerships between local healthcare providers and international nuclear medicine companies, combined with growing patient awareness and physician adoption, will sustain the 17.2% CAGR trajectory through 2030..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • South Korea's nuclear medicine market will more than double from USD 159.3M (2025) to USD 352.5M (2030), driven by a 17.2% CAGR.
    • South Korea's aging demographic and high prevalence of cancer and cardiovascular diseases are primary growth catalysts for nuclear medicine adoption.
    • South Korea's government-backed healthcare initiatives and reimbursement policies strongly support expansion of nuclear medicine diagnostic and therapeutic services.
    • South Korea is positioned as a regional leader in nuclear medicine technology adoption, with advanced PET-CT and SPECT infrastructure driving market competitiveness.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 15.1% from 2025 to 2030
    Largest Segment DIAGNOSTIC NUCLEAR MEDICINE (Type)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2030)
    Segments Covered Type

    South Korea Nuclear Medicine Market Report Segmentation

    1 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes
    • Diagnostic Nuclear Medicine
    • F-18
    • Ga-67
    • I-123
    • I-131
    • Lu-177
    • Other Beta Emitters
    • Other Pet Radiopharmaceuticals
    • Other Spect Radiopharmaceuticals
    • Pet Radiopharmaceuticals
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Tl-201
    • Y-90

    Target Audience

    • Medical Device Manufacturers : Manufacturers of PET-CT scanners, gamma cameras, and imaging equipment need South Korea-specific market data to assess market potential, competitive positioning, and distribution channel strategies.
    • Radiopharmaceutical Companies : Pharmaceutical firms developing diagnostic and therapeutic radiopharmaceuticals require detailed insights into South Korea's regulatory pathways, reimbursement structures, and clinical adoption trends.
    • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in South Korea's healthcare sector need validated market sizing, growth projections, and competitive analysis to support investment thesis development.
    • Hospital & Diagnostic Center Operators : Healthcare facility managers planning nuclear medicine service expansion require market intelligence on demand drivers, patient demographics, and technology trends specific to South Korea.
    • Market Research & Consulting Firms : Research organizations and consultants serving healthcare clients need comprehensive South Korea market data to support client advisory work, benchmarking studies, and strategic planning initiatives.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise market valuation data for South Korea (USD 159.3M in 2025) with verified 17.2% CAGR projections through 2030, enabling accurate financial forecasting and investment decisions.
    • Competitive Landscape Intelligence : Understand market dynamics specific to South Korea's healthcare ecosystem, including key players, market share distribution, and competitive positioning to inform market entry or expansion strategies.
    • Demographic & Clinical Insights : Access detailed analysis of South Korea's aging population trends, disease prevalence patterns, and clinical adoption rates to identify high-potential market segments and therapeutic areas.
    • Regulatory & Reimbursement Framework : Gain comprehensive understanding of South Korea's regulatory environment, reimbursement policies, and healthcare spending patterns to navigate market entry and pricing strategies effectively.
    • Strategic Growth Opportunities : Identify emerging opportunities in radiopharmaceutical development, imaging technology adoption, and partnership potential within South Korea's rapidly expanding nuclear medicine ecosystem.

    Frequently asked questions

    What is the current size of South Korea's nuclear medicine market?

    South Korea's nuclear medicine market is valued at USD 159.3 million in 2025 and is projected to grow to USD 352.5 million by 2030.

    What is the expected growth rate for South Korea's nuclear medicine market?

    South Korea's nuclear medicine market is expected to grow at a compound annual growth rate (CAGR) of 17.2% from 2025 to 2030.

    What factors are driving growth in South Korea's nuclear medicine market?

    Key drivers include South Korea's aging population, rising prevalence of chronic diseases, advanced healthcare infrastructure, government support for medical innovation, and increasing adoption of precision medicine approaches.

    Which applications are most prominent in South Korea's nuclear medicine market?

    South Korea's nuclear medicine market is primarily driven by oncology, cardiology, and neurology applications, with PET-CT and SPECT imaging modalities leading diagnostic adoption.

    How does South Korea's nuclear medicine market compare to global trends?

    South Korea's nuclear medicine market CAGR of 17.2% significantly exceeds the global CAGR of 15.1%, reflecting stronger regional demand and healthcare investment dynamics.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status